Multi-criteria decision analysis for health technology assessment in Canada: Insights from an expert panel discussion

Vakaramoko Diaby, Ron Goeree, Jeffrey S Hoch, Uwe Siebert

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Multi-criteria decision analysis (MCDA), a decision-making tool, has received increasing attention in recent years, notably in the healthcare field. For Canada, it is unclear whether and how MCDA should be incorporated into the existing health technology assessment (HTA) decision-making process. To facilitate debate on improving HTA decision-making in Canada, a workshop was held in conjunction with the 8th World Congress on Health Economics of the International Health Economics Association in Toronto, Canada in July 2011. The objective of the workshop was to discuss the potential benefits and challenges related to the use of MCDA for HTA decision-making in Canada. This paper summarizes and discusses the recommendations of an expert panel convened at the workshop to discuss opportunities and concerns with reference to the implementation of MCDA in Canada.

Original languageEnglish (US)
Pages (from-to)13-19
Number of pages7
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume15
Issue number1
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

Biomedical Technology Assessment
Decision Support Techniques
Canada
Decision Making
Education
Economics
Health
Delivery of Health Care

Keywords

  • Canada
  • decision-making
  • health technology assessment
  • healthcare
  • multi-criteria decision analysis
  • workshop

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Cite this

Multi-criteria decision analysis for health technology assessment in Canada : Insights from an expert panel discussion. / Diaby, Vakaramoko; Goeree, Ron; Hoch, Jeffrey S; Siebert, Uwe.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 15, No. 1, 01.02.2015, p. 13-19.

Research output: Contribution to journalReview article

@article{8e41bd7df49c484482e69118d9e25473,
title = "Multi-criteria decision analysis for health technology assessment in Canada: Insights from an expert panel discussion",
abstract = "Multi-criteria decision analysis (MCDA), a decision-making tool, has received increasing attention in recent years, notably in the healthcare field. For Canada, it is unclear whether and how MCDA should be incorporated into the existing health technology assessment (HTA) decision-making process. To facilitate debate on improving HTA decision-making in Canada, a workshop was held in conjunction with the 8th World Congress on Health Economics of the International Health Economics Association in Toronto, Canada in July 2011. The objective of the workshop was to discuss the potential benefits and challenges related to the use of MCDA for HTA decision-making in Canada. This paper summarizes and discusses the recommendations of an expert panel convened at the workshop to discuss opportunities and concerns with reference to the implementation of MCDA in Canada.",
keywords = "Canada, decision-making, health technology assessment, healthcare, multi-criteria decision analysis, workshop",
author = "Vakaramoko Diaby and Ron Goeree and Hoch, {Jeffrey S} and Uwe Siebert",
year = "2015",
month = "2",
day = "1",
doi = "10.1586/14737167.2015.965155",
language = "English (US)",
volume = "15",
pages = "13--19",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Multi-criteria decision analysis for health technology assessment in Canada

T2 - Insights from an expert panel discussion

AU - Diaby, Vakaramoko

AU - Goeree, Ron

AU - Hoch, Jeffrey S

AU - Siebert, Uwe

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Multi-criteria decision analysis (MCDA), a decision-making tool, has received increasing attention in recent years, notably in the healthcare field. For Canada, it is unclear whether and how MCDA should be incorporated into the existing health technology assessment (HTA) decision-making process. To facilitate debate on improving HTA decision-making in Canada, a workshop was held in conjunction with the 8th World Congress on Health Economics of the International Health Economics Association in Toronto, Canada in July 2011. The objective of the workshop was to discuss the potential benefits and challenges related to the use of MCDA for HTA decision-making in Canada. This paper summarizes and discusses the recommendations of an expert panel convened at the workshop to discuss opportunities and concerns with reference to the implementation of MCDA in Canada.

AB - Multi-criteria decision analysis (MCDA), a decision-making tool, has received increasing attention in recent years, notably in the healthcare field. For Canada, it is unclear whether and how MCDA should be incorporated into the existing health technology assessment (HTA) decision-making process. To facilitate debate on improving HTA decision-making in Canada, a workshop was held in conjunction with the 8th World Congress on Health Economics of the International Health Economics Association in Toronto, Canada in July 2011. The objective of the workshop was to discuss the potential benefits and challenges related to the use of MCDA for HTA decision-making in Canada. This paper summarizes and discusses the recommendations of an expert panel convened at the workshop to discuss opportunities and concerns with reference to the implementation of MCDA in Canada.

KW - Canada

KW - decision-making

KW - health technology assessment

KW - healthcare

KW - multi-criteria decision analysis

KW - workshop

UR - http://www.scopus.com/inward/record.url?scp=84937000132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937000132&partnerID=8YFLogxK

U2 - 10.1586/14737167.2015.965155

DO - 10.1586/14737167.2015.965155

M3 - Review article

C2 - 25267699

AN - SCOPUS:84937000132

VL - 15

SP - 13

EP - 19

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 1

ER -